Anti-MUC1 CAR-T cell therapy (PersonGen)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAnti-MUC1 CAR-T cell therapy (PersonGen)
Drug Alias NameAnti-Mucin1 (MUC1) CART cell therapy - PersonGen BiomedicineAnti-Mucin1 specific CART cellsAnti-Mucin1 CART cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMucin-1 inhibitors
TargetsMucin-1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBrain NeoplasmsPancreatic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungBrain NeoplasmsPancreatic Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A